15. Atezolizumab: Unlocking the Power of Immunotherapy
Finally, we round up our list of top thyroid cancer medications with Atezolizumab, another exciting entrant in the realm of immunotherapy. Like Tiragolumab, Atezolizumab is a checkpoint inhibitor, but it targets a different protein: PD-L1.
PD-L1 is a protein expressed on the surface of some cancer cells, allowing them to evade detection by the immune system. Atezolizumab works by blocking PD-L1, thereby enhancing the immune system’s ability to recognize and destroy cancer cells.
Atezolizumab has demonstrated effectiveness in various cancer types, and early evidence suggests that it may also have potential in advanced thyroid cancers that have become resistant to other treatments. The possibility of enhancing the immune response to thyroid cancer is a promising avenue, potentially providing a new line of defense for patients with this disease.
Like other immunotherapies, Atezolizumab can cause immune-related side effects such as skin rash, fatigue, and digestive issues. However, these are usually manageable with careful monitoring and appropriate interventions. Despite these challenges, the potential benefits of Atezolizumab underscore the increasing importance of immunotherapy in thyroid cancer treatment. (15)
